Fox Chase Cancer Center: Choice of First-Line Platinum Regimen Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Bladder Cancer

Press/Media

PeriodJun 4 2021

Media coverage

2

Media coverage